NLRP3 and atherosclerosis: Corilagin exerts the anti-atherosclerosis efficacy by inhibiting the Olfr2 signaling pathway in vitro and in vivo, leading to the suppression of NLRP3 inflammasome activation, reducing inflammatory cytokines expression, M1 macrophage polarization, and expression of pyroptosis-related molecule.